In unselected breast cancer patient groups treated with NeST approximately 20-26% of the cases can achieve pCR but this rate is significantly higher in HER2-positive and triple-negative breast cancer (TNBC) subtypes achieving pCR rates of up to 50-60% (7–9). This evidence concerns the gene ERBB2 and breast cancer.